Treatment of diffuse subretinal fibrosis uveitis with rituximab

Kurt Spiteri Cornish, Lucia Kuffova, John Forrester

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.

Original languageEnglish
Pages (from-to)153-154
Number of pages2
JournalBritish Journal of Ophthalmology
Issue number2
Early online date30 May 2014
Publication statusPublished - Feb 2015


  • Diffuse subretinal fibrosis uvetis (DUS)
  • rituximab
  • treatment


Dive into the research topics of 'Treatment of diffuse subretinal fibrosis uveitis with rituximab'. Together they form a unique fingerprint.

Cite this